I heard we are waiting for LLY to announce results from their Alzheimer's drug which is slated to be released months ahead of Biogen's to get some type of feel for how these will be accepted.
If this were a dividend paying stock (i.e. AMGN) I doubt we would have seen this severe of a reaction. That being said, I am looking at a low of $246.74 on March 29 which somewhat represents a double-bottom. Not saying we have to hit this level but we need to push back above $270 to be back above the 50 sma. This was a brutal selloff with a falloff below all the major sma's (10, 50 and 200). I also notice the Chief Information Officer recently left. I wonder if this had anything to do with the drug trial disappointment. Let's hope we see some upside today after this overreaction.
The street is reacting as if it were a one trick pony company. Is this their major source of future revenue growth or is there just fear that subsequent drug trials will also fail to impress? Anyone? I'm baffled that we see a 13% drop from this report.
Puzzled as to why hd is getting slammed this morning.
Gotta get past this Friday's jobs report, then BIIB shareholder's meeting slated for next wedn. June 8, then we'll see. Very possible if everything pans out okay.
not sure if this was bottom in market but perhaps fears of the rate hike are abating. market is like spoiled brat!
All the biotech ETF's are getting hammered. Guilty by association. I own GILD, AMGN, BIIB and can't see anything but a sea of red.
They upgraded TSLA knowing damned well they were going to announce a secondary in ah of which they are an underwriter of. Stock soured on the upgrade to only dump on its shareholders as soon as the announcement was made! SEC?? Duh!!!! That can't be right!